Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid.
CSF-stabilizing reagents
LC-MS/MS
biomarkers
cerebrospinal fluid (CSF)
high-abundant protein depletion
leptomeningeal metastasis (LM)
modelling leptomeningeal disease
protein microarrays
protein-based biomarker
proteomic analysis
tumor infiltrating
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Jan 2022
17 Jan 2022
Historique:
received:
24
11
2021
revised:
04
01
2022
accepted:
06
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
In the present work, leptomeningeal disease, a very destructive form of systemic cancer, was characterized from several proteomics points of view. This pathology involves the invasion of the leptomeninges by malignant tumor cells. The tumor spreads to the central nervous system through the cerebrospinal fluid (CSF) and has a very grim prognosis; the average life expectancy of patients who suffer it does not exceed 3 months. The early diagnosis of leptomeningeal disease is a challenge because, in most of the cases, it is an asymptomatic pathology. When the symptoms are clear, the disease is already in the very advanced stages and life expectancy is low. Consequently, there is a pressing need to determine useful CSF proteins to help in the diagnosis and/or prognosis of this disease. For this purpose, a systematic and exhaustive proteomics characterization of CSF by multipronged proteomics approaches was performed to determine different protein profiles as potential biomarkers. Proteins such as PTPRC, SERPINC1, sCD44, sCD14, ANPEP, SPP1, FCGR1A, C9, sCD19, and sCD34, among others, and their functional analysis, reveals that most of them are linked to the pathology and are not detected on normal CSF. Finally, a panel of biomarkers was verified by a prediction model for leptomeningeal disease, showing new insights into the research for potential biomarkers that are easy to translate into the clinic for the diagnosis of this devastating disease.
Identifiants
pubmed: 35053611
pii: cancers14020449
doi: 10.3390/cancers14020449
pmc: PMC8773653
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nat Biotechnol. 2015 Jan;33(1):22-4
pubmed: 25574629
Proteomics. 2015 Jan;15(1):10-5
pubmed: 25307358
Oncotarget. 2011 Oct;2(10):752-60
pubmed: 21987585
Curr Opin Neurol. 2016 Dec;29(6):797-805
pubmed: 27661208
Nucleic Acids Res. 2016 Jan 4;44(D1):D457-62
pubmed: 26476454
Crit Rev Clin Lab Sci. 2017 May;54(3):185-204
pubmed: 28393582
Clin Cancer Res. 2020 May 1;26(9):2163-2175
pubmed: 31924735
Mol Syst Biol. 2020 Jun;16(6):e9356
pubmed: 32485097
Neuroscience. 2017 Jun 23;354:69-87
pubmed: 28456718
Nucleic Acids Res. 2015 Jan;43(Database issue):D764-70
pubmed: 25593349
Nucleic Acids Res. 2014 Jan;42(Database issue):D472-7
pubmed: 24243840
Nat Biotechnol. 2014 Mar;32(3):223-6
pubmed: 24727771
Nucleic Acids Res. 2016 Dec 15;44(22):11033
pubmed: 27683222
Methods Mol Biol. 2019;1871:107-122
pubmed: 30276735
Clin Exp Metastasis. 2015 Apr;32(4):383-91
pubmed: 25795393
Front Oncol. 2021 Jun 03;11:685786
pubmed: 34150651
Mol Syst Biol. 2017 Sep 26;13(9):942
pubmed: 28951502
Electrophoresis. 2011 Nov;32(21):2966-74
pubmed: 21997478
Methods Mol Biol. 2019;2044:303-318
pubmed: 31432421
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Fluids Barriers CNS. 2017 Aug 14;14(1):22
pubmed: 28806983
Indian J Cancer. 2014 Oct-Dec;51(4):410-3
pubmed: 26842139
Mol Cell Proteomics. 2010 Nov;9(11):2497-507
pubmed: 20682762
J Neurooncol. 2018 Mar;137(1):1-10
pubmed: 29192390
Med Oncol. 2013 Jun;30(2):538
pubmed: 23504338
Clin Transl Med. 2014 Mar 29;3(1):7
pubmed: 24679154
Neuro Oncol. 2020 May 15;22(5):675-683
pubmed: 32352148
Nanomaterials (Basel). 2020 Jun 29;10(7):
pubmed: 32610601
Clin Transl Oncol. 2011 Mar;13(3):156-61
pubmed: 21421460
Transl Res. 2012 Apr;159(4):197-204
pubmed: 22424424
Anal Biochem. 2014 Apr 1;450:37-45
pubmed: 24440232
Nucleic Acids Res. 2016 Jan 4;44(D1):D481-7
pubmed: 26656494
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Onco Targets Ther. 2021 Apr 01;14:2327-2335
pubmed: 33833530
J Clin Oncol. 2008 Jan 1;26(1):96-105
pubmed: 18056677
Crit Rev Immunol. 2004;24(4):267-96
pubmed: 15588226
Lancet Oncol. 2010 Sep;11(9):871-9
pubmed: 20598636
Science. 2020 Jul 17;369(6501):276-282
pubmed: 32675368
Mol Cell Proteomics. 2005 Dec;4(12):2010-21
pubmed: 16249172
Nat Protoc. 2007;2(8):1896-906
pubmed: 17703201
Ann Oncol. 2017 Jul 1;28(suppl_4):iv84-iv99
pubmed: 28881917
Anal Chem. 1996 Mar 1;68(5):850-8
pubmed: 8779443
Cancers (Basel). 2021 Jun 09;13(12):
pubmed: 34207653
Sensors (Basel). 2012;12(2):2284-308
pubmed: 22438764
Thorac Cancer. 2020 Mar;11(3):588-593
pubmed: 31944608
Biomed Rep. 2019 Aug;11(2):70-78
pubmed: 31338193
J Bioinform Comput Biol. 2005 Apr;3(2):185-205
pubmed: 15852500
Proteomics. 2013 Jan;13(1):22-4
pubmed: 23148064
Cancer Treat Rev. 2016 Feb;43:83-91
pubmed: 26827696
Cell. 2017 Mar 9;168(6):1101-1113.e13
pubmed: 28283064
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Cancer Control. 2017 Jan;24(1):42-46
pubmed: 28178711
Proteomics. 2011 Mar;11(5):996-9
pubmed: 21337703
Mol Cell Proteomics. 2005 Sep;4(9):1265-72
pubmed: 15958392
IEEE Trans Pattern Anal Mach Intell. 2005 Aug;27(8):1226-38
pubmed: 16119262
Zhongguo Fei Ai Za Zhi. 2020 Aug 20;23(8):646-654
pubmed: 32838487
J Clin Oncol. 2016 Jul 10;34(20):2404-15
pubmed: 27161972
JAMA Oncol. 2016 Jun 1;2(6):839
pubmed: 27100632
Bioinformatics. 2008 Nov 1;24(21):2534-6
pubmed: 18606607
J Proteome Res. 2017 May 5;16(5):1890-1899
pubmed: 28379711
Expert Rev Proteomics. 2017 Apr;14(4):363-372
pubmed: 28293970
Adv Exp Med Biol. 2017;974:85-96
pubmed: 28353226